Assessing the Risk and Potential of TransCode Therapeutics Inc’s (RNAZ) Stock

19h ago, source: newsheater

Based on TransCode Therapeutics Inc (RNAZ), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at -40.11. The debt to equity ...

RNAZ TransCode Therapeutics, Inc.

1d ago, source: Seeking Alpha

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers.

TransCode Therapeutics Reports 2023 Results; Provides Business Update

23d ago, source: Business Insider

BOSTON, April 03, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today ...

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

29d ago, source: Stockhouse

BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today ...

TransCode Therapeutics Announces Pricing of $7 Million Public Offering

1mon ago, source: ADVFN

TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the pricing of its ...

TransCode Therapeutics, Inc. (RNAZ)

7d ago, source: Yahoo Finance

Clinical trial expected to commence in mid-2024 to evaluate the safety and preliminary anti-tumor activity of TTX-MC138BOSTON, April 15, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics ...

TransCode Therapeutics Reports 2023 Results; Provides Business Update

23d ago, source: Stockhouse

BOSTON, April 03, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported ...

TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

29d ago, source: Finanznachrichten

BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced ...

TransCode Therapeutics Inc RNAZ

5d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

TransCode Therapeutics, Inc.: TransCode Therapeutics Reports 2023 Results; Provides Business Update

1mon ago, source: Finanznachrichten

BOSTON, April 03, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today ...